文献速递瓣膜外科

生物瓣与机械瓣主动脉瓣置换术后再手术比较:STS数据库分析

Reoperation in Bioprosthetic vs Mechanical Aortic Valve Replacement in The Society of Thoracic Surgeons Database.
PubMed 文献 · Ann Thorac Surg · 2025-10-27

本研究基于STS成人心脏外科数据库,纳入140,516例首次孤立主动脉瓣置换患者,比较生物瓣与机械瓣置换后远期再手术与生存结局。经年龄特异性稳定逆概率加权及限制性立方样条风险调整后,机械瓣在≤63岁患者中再手术或全因死亡风险更低,63–72岁等效,≥72岁生物瓣更优。

要点

  • ≤63岁患者机械瓣主动脉瓣置换后风险调整再手术或全因死亡低于生物瓣。
  • 63–72岁患者两种瓣膜再手术或全因死亡风险等效。
  • ≥72岁患者生物瓣主动脉瓣置换再手术或全因死亡风险更优。

核心结论

  • 在≤63岁患者中,机械瓣主动脉瓣置换较生物瓣与更低的年龄校正后再手术或全因死亡风险相关。
  • 这些当代长期数据可进一步支持患者与医生在选择主动脉瓣人工瓣膜时的共享临床决策。

研究设计与样本

  • 基于STS成人心脏外科数据库识别所有首次孤立生物瓣或机械瓣主动脉瓣置换患者,并链接国家死亡指数获取全因死亡(2008–2019)。
  • 共纳入140,516例患者,其中生物瓣122,453例、机械瓣18,063例;研究期间29,048例发生主动脉瓣再手术(n=2,991)或死亡。
  • 排除年龄>80岁、心内膜炎、急诊/挽救性状态、休克、射血分数≤25%、任何既往心脏手术及未链接国家死亡指数者。
  • 采用年龄特异性稳定逆概率加权及限制性立方样条建模非线性年龄关系进行稳健风险调整。

主要发现

  • 风险调整后,免于再手术或全因死亡在至63岁 favoring 机械瓣,63–72岁等效,≥72岁生物瓣更优。
  • 年龄组特异性分析显示,机械瓣在≤65岁所有年龄组均与更低的再手术或全因死亡相关。

临床怎么用

  • ≤63岁主动脉瓣置换患者选择机械瓣可能降低远期再手术或死亡风险,应与患者共享决策。
  • 63–72岁患者两种瓣膜远期再手术或死亡风险等效,可结合其他因素个体化选择。
  • ≥72岁患者生物瓣在再手术或全因死亡方面更优,支持该年龄组优先考虑生物瓣。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The choice between bioprosthetic and mechanical surgical aortic valve replacement (AVR) should balance individual valve durability with patient life expectancy and the need for future reintervention. To inform clinical practice, this study aimed to evaluate contemporary, real-world, long-term outcomes of AVR reoperation and survival from The Society of Thoracic Surgeons Adult Cardiac Surgery Database. METHODS: All patients undergoing primary isolated bioprosthetic or mechanical AVR were identified. The database was used to define subsequent valve reoperation and link to the National Death Index for all-cause mortality (2008-2019). Patients aged >80 years, with endocarditis, emergency/salvage status, shock, ejection fraction ≤25%, any prior cardiac surgery, and nonlinkage to the National Death Index were excluded. Robust risk-adjustment was performed using age-specific stabilized inverse probability weighting and restricted cubic splines to model nonlinear age relationships. RESULTS: During the study period, 140,516 patients underwent bioprosthetic (n = 122,453) or mechanical (n = 18,063) AVR. A total of 29,048 underwent aortic valve reoperation (n = 2991) or died during the study period. After risk adjustment, freedom from reoperation or all-cause mortality favored mechanical valves to age 63 years, was equivalent between 63 and 72 years, and was superior in bioprosthetic AVR for age 72 years or older. Age group-specific analyses demonstrated mechanical valves to be associated with lower reoperation or all-cause mortality in all age groups ≤65 years. CONCLUSIONS: In patients aged ≤63 years, mechanical AVR was associated with lower risk-adjusted reoperation or all-cause mortality compared with bioprosthetic AVR. These contemporary long-term data further inform patient and provider shared clinical decision-making when choosing a prosthetic aortic valve.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kaneko T, Fukuhara S, Mehaffey JH, et al. Reoperation in Bioprosthetic vs Mechanical Aortic Valve Replacement in The Society of Thoracic Surgeons Database. Ann Thorac Surg. 2025. PMID: 41161559. doi:10.1016/j.athoracsur.2025.09.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。